30/03/2023 - Press release
Adding a peptide, a molecule made of several amino acids, to oxaliplatin, a chemotherapy drug used to treat colorectal cancer, avoids the side effects this treatment can have on normal cells, including potential chemotherapy resistance. This is confirmed by an article published in the Journal of Medicinal Chemistry, led by the Hospital del Mar Medical Research Institute and the Institute for Research in Biomedicine (IRB Barcelona). This work is the second part of a recent study that explored how platinum accumulation in normal cells promotes platinum resistance in colorectal cancer cells. This new approach prevents healthy cells surrounding the tumour from accumulating platinum. This avoids the activation of certain genes linked to poor treatment response and tumour progression.
21/02/2023 - Press release
A study led by researchers at the Hospital del Mar Medical Research Institute shows that the oxaliplatin administered in some cases of colorectal cancer accumulates in non-cancerous/healthy cells from the tumor environment. This accumulation causes healthy cells to produce a protein that further activates them, triggering tumor resistance to treatment and assisting in tumor regeneration. The researchers discovered a marker that can identify these tumors unresponsive to chemotherapy. The study, published in the journal Nature Communications, paves the way for new strategies enhancing the effects of chemotherapy on cancer cells while avoiding adverse side effects on non-cancerous cells.
13/01/23 - Events
The meeting, a success in terms of participation with more than 120 registered participants, has served to analyze the activity of the program and the strategic lines of growth. The Cancer Research Program of the Hospital del Mar Medical Research Institute held its annual meeting this morning, during which the main lines of the program were analyzed and the main challenges for the future were discussed. The initiative has been a success, with more than 120 people registered in the Josep Marull Room.
11/01/2023 - Press release
A study led by researchers from the Stem Cell and Cancer Research Group at the Hospital del Mar Medical Research Institute has revealed the key role a protein plays in identifying patients with T-cell acute lymphoblastic leukaemia who will not respond to standard treatment. The study, published in the journal EMBO Molecular Medicine, shows that combining chemotherapy with an inhibitor for this protein helps to eliminate treatment resistance in an animal model. This is a rare disease, which is diagnosed in around a hundred people each year in Spain, mainly paediatric patients.
21/12/2023 - Events
Research into immunotherapy for cancer at the Hospital del Mar Medical Research Institute has received a new boost thanks to a donation of 43,250 euros from the Friends of the Hospital del Mar Foundation. The president of the Friends of the Hospital del Mar Foundation, Xavier Trias, presented the cheque to the young researchers Marta Bort, Laura Ibáñez and Iván Pérez, on behalf of the research team looking into the Role of Interferon-Gamma in T cell-mediated elimination of breast cancer tumour cells, a project selected through the internal call for proposals "immunotherapy seed". This initiative is aimed at studying, through a proof of concept, some of the molecular mechanisms used by tumour cells to resist immunotherapy, with the goal of improving breast cancer treatments.
07/11/2022 - General information
At the same time, the head of the Haematological Cytology section of the Pathology Service of the Hospital del Mar and researcher at the Hospital del Mar Medical Research Institute, is secretary of the board of directors of the Spanish Group for Haematological Cytology and also holds the same position in the Spanish Group of Myelodysplastic Syndromes.
24/10/2022 - General information
Two of the grants are awarded by SEOM itself and the third by the Spanish Lung Cancer Group. Two research projects from the Hospital del Mar and the Hospital del Mar Medical Research Institute have received three grants of support during the congress of the Spanish Society of Medical Oncology, held in Madrid from October 18 to 21. The two projects will analyze different aspects related to immunological markers in different subtypes of lung cancer and in patients with different behaviors in response to immunotherapy.
20/10/2022 - General information
Ramon Diez-Feijóo Varela and Sílvia Ramos Campoy have received two personal grants to develop different research projects. Two researchers from the Hospital del Mar and the Hospital del Mar Medical Research Institute have received two grants from the Spanish Society of Hematology and Hemotherapy, within the framework of the LXIV congress of the organization, held in Barcelona from October 6 to 8. These are personal grants for one year, worth 36,000 euros, renewable for a second year.
19/10/2022 - Press release
A multicentre study involving hospitals in Spain and Portugal, led by Hospital del Mar, shows that these patients already receive enough radiation to treat the disease when the breast affected by the tumour is irradiated directly. The study monitored more than 400 women. The results indicate that the five-year survival rate and relapses are practically identical between those who underwent specific treatment targeting the nodes located in the armpits and those who only received breast radiation. The findings of the OPTIMAL study have been published in the journal Radiation Oncology and can now be applied to clinical practice. Thanks to this fact, patients will need less radiotherapy and will suffer fewer treatment-related side effects.
17/10/2022 - Institutional news
It will analyse the role the circadian rhythm alteration of intestinal microbiota plays in the development of Alzheimer's disease. The project is one of the sixty selected in the ninth call for applications for these grants, which reward highly innovative projects in nine areas of scientific knowledge and culture. The project by IMIM-Hospital del Mar researcher Patrick-Simon Welz, 'Losing the rhythm: host-microbiota circadian communication in Alzheimer's disease', is one of the 60 projects selected in the ninth edition of the Leonardo grants, awarded by the BBVA Foundation. These grants support highly innovative proposals in various scientific and cultural fields. This year, 884 applications were submitted and evaluated by 85 independent experts divided into nine panels.
© Institut Hospital del Mar
d'Investigacions MèdiquesLegal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact
